For instance, the early detection of EGFR mutations can prompt the initiation of targeted therapy with third-generation tyrosine kinase inhibitors, such as Osimertinib, thereby significantly improving the survival rate of lung cancer patients [44]. Here, EGFR is linked to lung carcinoma.